Drug Trial Radar · NCT06417775
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
496
Planned (sponsor's estimate)
Start
Sep 10, 2024
Primary completion
Nov 2027
Study completion Nov 2027
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- May 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A migraine is a moderate to severe headache typically on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. Menstrual migraine (MM) is defined as migraine attacks that occur within the perimenstrual period (PMP) in at least 2 out of 3 menstrual cycles. The PMP is from 2 days before the onset of menstrual bleeding to 2 days after. This study will assess how safe and effective ubrogepant is in treating menstrual migraine. Adverse Events and change in disease activity will be assessed. Ubrogepant is an investigational drug being developed for short-term prevention of menstrual migraine. Participants will be randomly assigned to one of the 2 groups to receive either ubrogepant or placebo. Around 496 adult female participants with menstrual migraine will be enrolled in approximately 100 sites in the United States and Puerto Rico. Participants will receive oral ubrogepant tablets once daily for 7 consecutive days starting 3 days prior to estimated onset of menses per cycle for 3 PMPs during double-blind period (16 weeks). Eligible participants may continue to receive oral ubrogepant tablets once daily for 7 consecutive days per cycle starting 3 days prior to estimated onset of menses during open-label extension period (52 weeks). There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will collect data daily in electronic diaries and attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions
- Migraine
Interventions
UbrogepantDrug
Oral Tablets
Placebo for UbrogepantDrug
Oral Tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Number of Migraine Days Occurring During Perimenstrual Periods (PMPs) Across the Double-Blind Treatment PeriodTime frame: Up to approximately 16 Weeks
- Number of Participants With Adverse Events (AEs)Time frame: Up to approximately 68 Weeks
Locations
106 sites in 2 countries. Site status is shown where the registry gives one.
Central Research Associates /ID# 260161
Birmingham, Alabama
Rehabilitation and Neurological Services /ID# 275593
Huntsville, Alabama
MD First Research - Chandler /ID# 262564
Chandler, Arizona
Gilbert Neurology /ID# 260179
Gilbert, Arizona
Foothills Research Center/CCT Research /ID# 260180
Phoenix, Arizona
Trialmed-Synexus Clinical Research US, Inc. - Tucson /ID# 258309
Tucson, Arizona
Preferred Research Partners /ID# 262786
Little Rock, Arkansas
Preferred Research Partners /ID# 273128
Little Rock, Arkansas
Hope Clinical Research /ID# 257867
Canoga Park, California
Axiom Research /ID# 257833
Colton, California
Neuro Pain Research Center /ID# 257155
Fresno, California
Axiom Research, LLC-Los Angeles /ID# 264085
Glendale, California
Sun Valley Research Center /ID# 257152
Imperial, California
Axiom Research - Irvine /ID# 264083
Irvine, California
CenExel Collaborative Neuroscience Research /ID# 257828
Los Alamitos, California
BNL Health - Los Angeles Headache Center /ID# 257237
Los Angeles, California
M3 Wake Research - Newport Beach /ID# 257158
Newport Beach, California
Artemis Institute for Clinical Research - San Diego /ID# 257134
San Diego, California
M3 Wake Research - Convoy /ID# 257897
San Diego, California
Optimus Medical /ID# 257856
San Francisco, California
New England Institute for Clinical Research /ID# 264019
Stamford, Connecticut
Neurology Offices of South Florida, PLLC /ID# 257161
Boca Raton, Florida
Accel Research Sites Network - DeLand Clinical Research Unit /ID# 257403
DeLand, Florida
Accel Research Sites - Lakeland Clinical Research Unit /ID# 257874
Lakeland, Florida
Well Pharma Medical Research /ID# 257199
Miami, Florida
Indago Research and Health Center /ID# 277943
Miami Lakes, Florida
Sensible Healthcare /ID# 257198
Ocoee, Florida
Clinical Neuroscience Solutions, Inc /ID# 257190
Orlando, Florida
Conquest Research /ID# 258314
Winter Park, Florida
NeuroTrials Research /ID# 274507
Atlanta, Georgia
Clinical Research Atlanta - Headlands LLC /ID# 260181
Stockbridge, Georgia
Hawaii Pacific Neuroscience /ID# 274469
Honolulu, Hawaii
Velocity Clinical Research - Boise /ID# 257135
Meridian, Idaho
Healthcare Research Network /ID# 257868
Tinley Park, Illinois
Deaconess Midtown Hospital /ID# 257400
Evansville, Indiana
Accellacare - McFarland Clinic /ID# 257834
Ames, Iowa
Alliance for Multispecialty Research LLC /ID# 257839
Newton, Kansas
Collective Medical Research /ID# 257131
Overland Park, Kansas
Alliance For Multispeciality Research - Wichita East /ID# 257148
Wichita, Kansas
Tandem Clinical Research - Marrero - Barataria Boulevard /ID# 260146
Marrero, Louisiana
Showing 40 of 106 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.